NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
TRAVATAN (travoprost) by Alcon is acid, a prostaglandin analog is a selective fp prostanoid receptor agonist, which is believed to reduce iop by increasing uveoscleral outflow. Approved for ocular hypertension, open-angle glaucoma, glaucoma. First approved in 2001.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVATAN is a prostaglandin analog ophthalmic solution containing travoprost, a selective FP prostanoid receptor agonist approved in 2001 for treatment of ocular hypertension and open-angle glaucoma. It reduces intraocular pressure (IOP) by increasing uveoscleral outflow of aqueous humor, though the exact mechanism remains incompletely understood.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (score: 30/100), suggesting team consolidation and shift toward lifecycle management and generic transition planning.
Mechanism of Action
acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Indications (3)
Worked on TRAVATAN at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.